Who is sponsoring CIVIMEC?

CIVIMEC is sponsored by Ciusss de L'Est de l'Île de Montréal.

What condition does CIVIMEC study?

CIVIMEC studies Quality of Recovery, Anesthesia, Postoperative Pain, Cesarean Section.

What drugs are being tested in CIVIMEC?

Interventions: Intrathecal Morphine, Ropivacaine 0.2%.

What is the status of CIVIMEC?

CIVIMEC is currently WITHDRAWN.

Last reviewed 2024-02-19 · How we verify

Improving ObsQoR-11 With Continuous Wound Infusion Versus Intrathecal Morphine After Elective Cesarean Delivery: A Randomized Double-Blinded Controlled Trial Targeting Patients' Recovery and Satisfaction (CIVIMEC)

NCT05696678 NA WITHDRAWN

The purpose of this prospective randomized double-blinded and controlled study is to evaluate the quality of recovery after elective cesarean delivery using the Obstetric Quality-of-Recovery-11 (ObsQoR-11) score at 24 hours between patients receiving intrathecal morphine (ITM group) compared to patients receiving a ropivacaine continuous wound infusion (CWI group).

Details

Lead sponsor	Ciusss de L'Est de l'Île de Montréal
Phase	NA
Status	WITHDRAWN
Start date	2023-02
Completion	2023-11

Conditions

Quality of Recovery
Anesthesia
Postoperative Pain
Cesarean Section

Interventions

Intrathecal Morphine
Ropivacaine 0.2%

Primary outcomes

ObsQoR-11 at 24 hours — 24 hours after end of surgery
Quality of recovery after cesarean delivery using ObsQoR-11 score at 24 hours between patients receiving intrathecal morphine (ITM) compared to patients receiving a ropivacaine continuous wound infusion CWI)

Countries

Canada